Clinical use of angiogenesis biomarkers in fetal growth restriction: a narrative review
Angiogenesis biomarkers, particularly sFlt-1 and PlGF, represent valuable tools for predicting, diagnosing, and monitoring FGR. Their integration into clinical practice could optimize risk stratification and management, ultimately reducing adverse perinatal outcomes.
Authors
- Cecilia Villalaín (ORCID: https://orcid.org/0000-0002-9456-4100)
- Alberto Galindo (ORCID: https://orcid.org/0000-0002-1308-1474)
- Ignacio Herraı̀z (ORCID: https://orcid.org/0000-0001-6807-4944)
- F. D'Antonio
Institutions
- Instituto de Salud Carlos III (ES)
- University of Chieti-Pescara (IT)
- Hospital Universitario 12 De Octubre (ES)
- Fetal Medicine Foundation (GB)
- Research Network (United States) (US)
- Instituto Nacional de la Salud (ES)
Publication Details
- Journal
- The Journal of Maternal-Fetal & Neonatal Medicine
- Published
- 2025-11-23
- DOI
- https://doi.org/10.1080/14767058.2025.2589630
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00